Haw ParHAWPF 96 EV-to-FCF is -11.38 as of Jun. 29, 2026. GuruFocus rates HAWPF with a GF Score™ of 96/100 and a GF Value™ of $8.94. The stock has 3 warning signs investors should review. Among 559 Drug Manufacturers companies, Haw Par ranks better than 99.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Haw Par's Enterprise Value is $-486.4 Mil.
Haw Par's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $42.7 Mil. Therefore, Haw Par's EV-to-FCF for today is -11.38.
The historical rank and industry rank for Haw Par's EV-to-FCF or its related term are showing as below:
HAWPF'
s EV-to-FCF Range Over the Past 10 Years
Min: -77.98 Med: -9.76 Max: 12.18
Current: -11.47
During the past 13 years, the highest EV-to-FCF of Haw Par was 12.18. The lowest was -77.98. And the median was -9.76.
HAWPF's EV-to-FCF is ranked better than 99.82% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs HAWPF: -11.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haw Par's share price for today is $12.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.933.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Haw Par EV-to-FCF Related Terms
Haw Par EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Haw Par's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Haw Par's EV-to-FCF falls into.
Haw Par's current Enterprise Value is $-486.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $42.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a EV-to-FCF of -11.38 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haw Par and its competitors. According to the industry distribution chart, Haw Par ranks #1 out of 559 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is Haw Par's EV-to-FCF too high?
Haw Par's current EV-to-FCF is -11.38. Based on the distribution chart, Haw Par ranks #1 out of 559 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #1 out of 559 companies for EV-to-FCF. This places Haw Par in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current EV-to-FCF is -11.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current EV-to-FCF of -11.38. The stock's GF Value™ is $8.94, compared to a current price of $12.00 — trading 34.2% above its estimated fair value. The current EV-to-FCF is -11.38. Haw Par's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Haw Par (HAWPF), the current EV-to-FCF is -11.38 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.2% above its estimated GF Value™ of $8.94.
Key valuation signals for HAWPF:
EV-to-FCF: -11.38
GF Value™: $8.94 vs. price of $12.00 (34.2% above fair value)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
96GF Score
Get the complete analysis for HAWPF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
